Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.